SCHEMBL2919611

SCHEMBL2919611

Cc1ccc(Nc2ncc3cccc(C)c3n2)cc1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.51
KDM4E B2RXH2 1/20 0.51
GAA P10253 1/20 0.51
STK17A Q9UEE5 2/20 0.51
SRC P12931 1/20 0.51
STK17B O94768 1/20 0.48
MAPK10 P53779 2/20 0.46
JUN P05412 1/20 0.46
SYK P43405 1/20 0.45
JAK2 O60674 2/20 0.44
PTGS1 P23219 1/20 0.43
PTGS2 P35354 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
TAAR1 Q96RJ0 1/20 0.43
JAK1 P23458 1/20 0.42
TYK2 P29597 1/20 0.42
JAK3 P52333 1/20 0.42
ULK1 O75385 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2916705 0.87 KDR (0.52) SRCMAPK10JUNSYKJAK2
SCHEMBL2911814 0.83 MAPK10 (0.53) STK17AMAPK10JUNSYKPTGS1
SCHEMBL12999377 0.83 ABL1 (0.58) SRCSYKAURKACDK4CDK2
SCHEMBL2912369 0.83 SYK (0.56) GAASRCSYKJAK2PTGS1
SCHEMBL2913599 0.83 KDR (0.56) SYKPTGS1PTGS2AURKACDK1
SCHEMBL2922769 0.83 SYK (0.67) GAASRCSYKAURKACDK1
SCHEMBL12999380 0.82 JAK2 (0.52) MAPK10JUNJAK2JAK1TYK2
SCHEMBL12999378 0.82 AURKA (0.60) SRCMAPK10SYKAURKACDK1
Hydrochloric Acid SCHEMBL2916265 0.82 ABL1 (0.57) SRCSYKAURKACDK4CDK2
SCHEMBL2919987 0.81 STK17A (0.54) STK17ASTK17BMAPK10JUNSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE CARNA BIOSCIENCES INC. (JP) 2010-12-09 US disclosed
EP-2226315-A1 2-AMINOQUINAZOLINE DERIVATIVE Carna Biosciences Inc. (JP) 2010-09-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311965-A1 2-AMINOQUINAZOLINE DERIVATIVE DSTYK, ABL1, EEF2K L3MBTL1 1868/4885KDM4E 431/4885GAA 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.